• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Shire to pay feds $350m to settle Dermagraft kickbacks case

January 12, 2017 By Sarah Faulkner

Shire to pay feds $350m to settle Dermagraft kickbacks caseThe U.S. Justice Dept. said yesterday that Shire (NSDQ:SHPG) and its subsidiaries will cough up $350 million to settle allegations that Shire and the company it acquired in 2011, Advanced BioHealing, gave kickbacks to clinics and physicians in exchange for using its bioengineered human skin substitute, Dermagraft.

“This settlement represents the largest False Claims Act recovery by the United States in a kickback case involving a medical device,” principal deputy assistant attorney general Benjamin Mizer said in prepared remarks. “Kickbacks by suppliers of healthcare goods and services cast a pall over the integrity of our health care system. Patients deserve the unfettered, independent judgement of their health care professionals.”

The federal and state False Claims Act allegations accuse the company of providing lavish dinners, drinks, entertainment, travel and more to clinics and physicians in the hopes that they would use Dermagraft in their practices. The United States said that the company violated anti-kickback statutes and anti-bribery statutes, therefore submitting hundreds of millions of dollars of false claims to federally-funded health care programs for Dermagraft.

“Flagrant and systemic kickback activity of the type at issue in this case is designed to impair and undermine a physician’s independent medical judgement, and will not be tolerated,” Middle District of Florida’s U.S. Attorney A. Lee Bentley III said. “This lawsuit and today’s historic settlement demonstrate our office’s vigilant and on-going efforts to safeguard federal health care program beneficiaries from the effects of such illegal and deplorable conduct.”

The middle district of Florida has obtained criminal convictions for 3 Shire executives and a number of healthcare providers who received kickbacks as a part of the scheme, according to the U.S. Justice Dept.

“U.S. Dept. of Veterans Affairs healthcare providers are obligated to render care free of any improper financial influences” Dept. of Veterans Affairs’ special agent in charge Michael Seitler said. “This is particularly important at VA, since we care for many of this nation’s heroes who have sacrificed their own welfare for our freedom. In this case, ABH saw a dramatic rise in its sales to the VA during the period of time it provided illegal inducements to multiple VA clinicians across the country. These corrupt practices served to erode the public trust in our healthcare system. The VA [office of inspector general] is committed to investigating, and bringing to justice, those who engage in these illegal practices.”

The settlement also resolved allegations that Shire and Advanced BioHealing made false statements to inflate the price of Dermagraft and marketed it for uses that are not approved by the FDA.

“Patients must be able to trust that decisions made by their doctors are based on unbiased professional judgement and not personal gain,” HHS inspector general’s chief counsel Gregory Demske said. “The office of the inspector general will continue to monitor Shire’s compliance with federal healthcare programs through its oversight of Shire’s Corporate Integrity Agreement.”

Filed Under: Diabetes, Featured, Legal News, Wall Street Beat Tagged With: Advanced BioHealing, Shire, U.S. Justice Dept.

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS